Head-to-head trial of two diabetes drugs yields mixed results

November 6, 2012, University of North Carolina Health Care
“The results of this study will be helpful to both doctors and patients in shared decision-making about which of these two drugs is better suited for a particular patient,” said John B. Buse, M.D., Ph.D., first author of the study. Dr. Buse is division chief of endocrinology and metabolism in the University of North Carolina School of Medicine and director of the UNC Diabetes Care Center. Credit: UNC Medical Center News Office

A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded mixed results.

The 26-week, multicenter DURATION-6 clinical trial found that daily injections of liraglutide (Victoza) were slightly more effective than weekly injections of (Bydureon) in lowering blood sugar and promoting weight loss in patients with . However, the patients taking exenatide suffered fewer negative side effects such as nausea, diarrhea and vomiting.

"Both of these agents are very exciting diabetes products and really good blood sugar-lowering drugs," said John B. Buse, MD, PhD, first author of the study, division chief of in the University of North Carolina School of Medicine, director of the UNC Diabetes Care Center and a a PI Extender of the UNC NIH Clinical and Translational Science Awards (CTSA).

"The results of this study will be helpful to both doctors and patients in shared decision-making about which of these two drugs is better suited for a particular patient."

"The results of this study will be helpful to both doctors and patients in shared decision-making about which of these two drugs is better suited for a particular patient," Buse said. "For example, for some patients the additional weight loss advantage provided by liraglutide might tip the scales in favor of that drug. For other patients, though, the greater convenience of once-weekly injections and the more favorable side effects profile of exenatide would be extremely appealing."

Results of the study were published online ahead of print on Nov. 7, 2012 by The .

In the study, 912 patients from 105 sites in 19 countries were randomized to receive injections of once-daily liraglutide or once-weekly exenatide for 26 weeks. The primary endpoint of the study was the overall reduction in HbA1c (blood sugar) levels from baseline to 26 weeks.

Both drugs produced a clinically significant decrease in . By the end of the study, 60 percent of the patients taking liraglutide had achieved HbA1c levels of less than 7 percent, vs. 53 percent of patients on exenatide. Both drugs also produced progressive decreases in bodyweight, but patients taking liraglutide lost about 2 pounds more weight than those on exenatide.

Patients in both groups reported having side effects on occasions over the six month trial. The most common were nausea (21 percent in the liraglutide group vs. 9 percent in the exenatide group), diarrhea (13 percent vs. 6 percent) and vomiting (11 percent vs. 4 percent). The occurrence of side effects lessened in both groups over time. Five percent of on liraglutide and 3 percent on exenatide dropped out of the study because of .

Explore further: Liraglutide with insulin improves poorly controlled Type 1 diabetes

Related Stories

Liraglutide with insulin improves poorly controlled Type 1 diabetes

June 25, 2012
Obese adults with poorly controlled Type 1 diabetes can better control their blood sugar by adding liraglutide, a Type 2 diabetes drug, to their insulin therapy, a new study finds. The results, which will be presented at ...

Exenatide (Byetta) has rapid, powerful anti-inflammatory effect, study shows

November 2, 2011
Exenatide, a drug commonly prescribed to help patients with type 2 diabetes improve blood sugar control, also has a powerful and rapid anti-inflammatory effect, a University at Buffalo study has shown.

Study suggests drug significantly improves glycemic control in type one diabetics on insulin

June 15, 2011
Results of a small, observational study conducted at the University at Buffalo suggest that liraglutide, an injectable medication used to treat type 2 diabetes, also helps type 1 diabetics on insulin achieve optimal control ...

Recommended for you

Some viruses produce insulin-like hormones that can stimulate human cells—and have potential to cause disease

February 19, 2018
Every cell in your body responds to the hormone insulin, and if that process starts to fail, you get diabetes. In an unexpected finding, scientists at Joslin Diabetes Center have identified four viruses that can produce insulin-like ...

Researchers discover link between gut and type 1 diabetes

February 19, 2018
Scientists have found that targeting micro-organisms in the gut, known as microbiota, could have the potential to help prevent type 1 diabetes.

Researchers find existing drug effective at preventing onset of type 1 diabetes

February 15, 2018
A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz ...

Chemist designs diabetic treatment minus harmful side effects

February 9, 2018
A chemist in the College of Arts and Sciences (A&S) has figured out how to control glucose levels in the bloodstream without the usual side effects of nausea, vomiting or malaise.

Peptide improves glucose and insulin sensitivity, lowers weight in mice

February 8, 2018
Treating obese mice with catestatin (CST), a peptide naturally occurring in the body, showed significant improvement in glucose and insulin tolerance and reduced body weight, report University of California San Diego School ...

Study reports use of nutritional ketosis with mobile app intervention could reverse Type 2 diabetes

February 7, 2018
A newly published study has shown that an individualized approach to nutritional ketosis (utilizing fat rather than glucose to fuel the body), combined with remote monitoring via a mobile application, could sustainably and ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.